Diagnostic and Predictive Recurrence Value of Plasma Fibrinogen in Patients With Adrenocortical Carcinoma

被引:0
作者
Ma, Chengquan [1 ]
Yang, Bin [2 ]
Mao, Quanzong [3 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Dept Urol, 154 Anshan Rd, Tianjin 300052, Peoples R China
[2] Qingdao Univ, Dept Urol, Affiliated Hosp, Qingdao, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Urol, Beijing, Peoples R China
关键词
Fibrinogen; adrenocortical carcinoma; adrenal adenoma; recurrence; ROC curve; D-DIMER; PROGNOSIS; CANCER; EFFICACY; ALBUMIN; BENIGN;
D O I
10.1177/11795549241271657
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The correlation between fibrinogen levels and adrenocortical carcinoma (ACC) remains unclear. This study aimed to explore the value of preoperative plasma fibrinogen as a biomarker for ACC. METHODS: We identified 40 patients with ACC and 170 patients with adrenal adenoma (AA) who underwent surgery at our institution between 2015 and 2022. Plasma fibrinogen levels and postoperative tumor recurrence information of the patients were also recorded. For intergroup comparisons, data obtained from the AA and ACC groups were evaluated using a t-test. The cutoff value of fibrinogen level was determined using a receiver operating characteristic (HOC) curve. RESULTS: Mean fibrinogen levels in the AA and ACC groups were 2.81 +/- 0.59 g/L and 3.88 +/- 1.75 g/L, respectively (P < .001). Fibrinogen level, which can help distinguish between AA and ACC, was evaluated using the HOC curve. The cutoff fibrinogen level was estimated as 3.87 g/L according to the Youden index. With this value, the sensitivity was 62.5%, specificity was 95.7%, and the area under the HOC curve (AUC) was 0.74 (P < .001). Fibrinogen level, which can help distinguish between recurrence and non-recurrence, was evaluated using the HOC curve. The cutoff fibrinogen level was estimated as 3.96 g/L according to the Youden index. The sensitivity, specificity, and AUC were 90%, 71.4%, and 0.85, respectively (P < .001). CONCLUSION: According to the data in this study, plasma fibrinogen could be used to distinguish ACC from AA. Most importantly, plasma fibrinogen may be used to identify recurrence of postoperative ACC.
引用
收藏
页数:5
相关论文
共 37 条
  • [1] Impact of plasma fibrinogen levels in benign and malignant soft tissue tumors
    Asanuma, Kunihiro
    Matsumine, Akihiko
    Nakamura, Tomoki
    Matsubara, Takao
    Asanuma, Yumiko
    Oi, Toru
    Goto, Mikinobu
    Okuno, Kazuma
    Kakimoto, Takuya
    Yada, Yuuki
    Sudo, Akihiro
    [J]. CANCER BIOMARKERS, 2016, 16 (03) : 453 - 458
  • [2] What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
    Basile, Vittoria
    Puglisi, Soraya
    Altieri, Barbara
    Canu, Letizia
    Libe, Rossella
    Ceccato, Filippo
    Beuschlein, Felix
    Quinkler, Marcus
    Calabrese, Anna
    Perotti, Paola
    Berchialla, Paola
    Dischinger, Ulrich
    Megerle, Felix
    Baudin, Eric
    Bourdeau, Isabelle
    Lacroix, Andre
    Loli, Paola
    Berruti, Alfredo
    Kastelan, Darko
    Haak, Harm R.
    Fassnacht, Martin
    Terzolo, Massimo
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (04):
  • [3] Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors
    Boulle, N
    Logié, A
    Gicquel, C
    Perin, L
    Le Bouc, Y
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) : 1713 - 1720
  • [4] Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma
    Chen, Wei
    Shan, Boer
    Zhou, Shuling
    Yang, Huijuan
    Ye, Shuang
    [J]. BMC CANCER, 2022, 22 (01)
  • [5] Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Possible Prognostic Markers for Patients Undergoing Resection of Adrenocortical Carcinoma
    de Jong, Mechteld C.
    Mihai, Radu
    Khan, Shahab
    [J]. WORLD JOURNAL OF SURGERY, 2021, 45 (03) : 754 - 764
  • [6] Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer
    Dirix, Luc Y.
    Oeyen, Steffi
    Buys, Andy
    Liegois, Vincent
    Prove, Annemie
    Van de Mooter, Tom
    Van Laere, Steven
    Vermeulen, Peter B.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (03) : 583 - 591
  • [7] Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity
    Falanga, Anna
    Marchetti, Marina
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (06) : 1397 - 1408
  • [8] Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Fassnacht, M.
    Assie, G.
    Baudin, E.
    Eisenhofer, G.
    de la Fouchardiere, C.
    Haak, H. R.
    de Krijger, R.
    Porpiglia, F.
    Terzolo, M.
    Berruti, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (11) : 1476 - 1490
  • [9] European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
    Fassnacht, Martin
    Dekkers, Olaf M.
    Else, Tobias
    Gaudin, Eric
    Berruti, Alfredo
    de Krijger, Ronald R.
    Haak, Harm R.
    Mihail, Radu
    Assie, Guillaume
    Terzolo, Massimo
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 179 (04) : G1 - G46
  • [10] Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma
    Gaitanidis, Apostolos
    Wiseman, Douglas
    el Lakis, Mustapha
    Nilubol, Naris
    Kebebew, Electron
    Patel, Dhaval
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (08) : 1450 - 1455